NCT07588347Not yet recruiting
Construction and Preliminary Evaluation of Dyadic Acceptance and Commitment Therapy for Couples With Fear of Lung Cancer Recurrence
Source: ClinicalTrials.gov · Last updated 19 May 2026
Brief summary (registry, in English)
The goal of this clinical trial is to develop a simple, scientific, effective, and culturally adapted dyadic Acceptance and Commitment Therapy (ACT) intervention program (the ADAPT program) targeting fear of cancer recurrence (FCR) among lung cancer patients and their spouse caregivers. The study will also evaluate the feasibility, acceptability, and preliminary effectiveness of the ADAPT program. The main research questions are as follows: * Is the ADAPT intervention program feasible and acceptable for lung cancer patients and their spouse caregivers? * Compared with usual care, can the ADAPT intervention program preliminarily reduce FCR levels in both patients and their spouse caregivers? Can the program improve coping styles, illness perceptions, family functioning, and intimate relationships among both patients and their spouse caregivers? Can the program enhance psychological flexibility and quality of life (QOL) in both patients and their spouse caregivers? Researchers will compare the ADAPT intervention program with usual care to evaluate its preliminary effectiveness in reducing FCR among lung cancer patients and their spouse caregivers. Participants will: * Receive the ADAPT intervention twice during each radiotherapy and/or chemotherapy cycle, for a total of three treatment cycles (approximately 3 months); * Complete questionnaires at baseline (before the intervention), immediately after the intervention, and one month post-intervention; * Report outcomes including FCR severity, FCR triggers, psychological flexibility, illness perception, dyadic coping, family functioning, intimacy, and quality of life (QOL).
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 72 (estimated)
- First submitted
- 4 May 2026
- Start date
- 15 May 2026
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- Feifei Huang
- Diseases
- Lung cancer
- NCT number
- NCT07588347
What you commit to
- Study type: Interventional
- Planned participants: 72
- From 15 May 2026 to the primary completion date, 30 Jun 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Diagnosed mental disorders or currently receiving psychiatric treatment.
- Concurrent malignant tumors in other organs.
Other illness
- Presence of personality disorders, intellectual disability, memory disorders, brain injury, or neurological disease.
- History of upper limb fractures or surgery resulting in impaired hand function.
- Presence of serious comorbid conditions (e.g., respiratory failure, malignant tumors, or other critical illnesses).
Other
- Patients:
- Severe complications (e.g., chest pain and/or dyspnea due to pleural tumor invasion).
- Spouse caregiver unwilling to participate.
- Participation in other similar psychological interventions.
- Spouse Caregivers:
- Patient unwilling to participate.
- Participation in other research studies.
Who the study is looking for
- Patients:
- Diagnosis of primary lung cancer confirmed by pathological examination.
- Age ≥ 22 years for men and ≥ 20 years for women (legal marriage age in China).
- Have undergone lung cancer surgery and are scheduled to receive the first round of radiotherapy and/or chemotherapy treatment
- Fear of Cancer Recurrence Inventory-Short Form (FCRI-SF) score ≥ 13, indicating moderate-to-severe FCR.
- Eastern Cooperative Oncology Group (ECOG) ≤2.
- Aware of their diagnosis and willing to participate voluntarily.
- Normal cognitive function (Montreal Cognitive Assessment \[MoCA\] score ≥ 26), alert and conscious, and able and willing to communicate their thoughts.
- Spouse Caregivers:
- Identified by the patient as the primary caregiver, providing ≥ 50% of care in the past 2 weeks.
- Legally married to the patient.
- Age ≥ 22 years for men and ≥ 20 years for women.
- Normal cognitive function (MoCA score ≥ 26), no diagnosed mental disorders, able to communicate effectively, and willing to share their thoughts.
Age in the registry: 20 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.